SYK Stock Recent News

Portage, Michigan, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) today announced that it is commencing, through a wholly owned subsidiary, Eagle 1 Merger Sub, Inc., a cash tender offer to purchase all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80.00 per share in cash. The offer is being made pursuant to the previously announced merger agreement, dated as of January 6, 2025, among Stryker, Eagle 1 Merger Sub, Inc and Inari.

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inari Medical, Inc. (NasdaqGS: NARI) to Stryker (NYSE: SYK). Under the terms of the proposed transaction, shareholders of Inari will receive $80.00 in cash for each share of Inari that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the c.

SYK inks an agreement to acquire Inari Medical at a valuation of approximately $4.9 billion.

Inari Medical (NARI) stock skyrocketed Monday afternoon and again Tuesday morning after a report that it was close to being acquired by Stryker (SYK) proved to be true.

On Monday, Stryker Corporation SYK agreed to acquire Inari Medical Inc. NARI for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion.

Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion late Monday. Inari stock catapulted on the news.

Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) --  Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous thromboembolism (VTE) to Stryker. Inari's innovative product portfolio is highly complementary to Stryker's Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.

Medical-device maker Stryker is in advanced talks to acquire Inari Medical , which makes devices that treat patients with venous diseases, people familiar with the matter told Reuters on Monday.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.